These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34702068)

  • 1. Uncertainties and Controversies in the Management of Ischemic Stroke and Transient Ischemic Attack Patients With Patent Foramen Ovale.
    Kasner SE; Lattanzi S; Fonseca AC; Elgendy AY
    Stroke; 2021 Dec; 52(12):e806-e819. PubMed ID: 34702068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials.
    Vaduganathan M; Qamar A; Gupta A; Bajaj N; Golwala HB; Pandey A; Bhatt DL
    Am J Med; 2018 May; 131(5):575-577. PubMed ID: 29229471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Percutaneous Patent Foramen Ovale Closure Preventing Secondary Ischemic Stroke in Japan.
    Inoue S; Igarashi A; Iguchi Y; Akagi T
    J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105884. PubMed ID: 34153592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
    Furlan AJ; Reisman M; Massaro J; Mauri L; Adams H; Albers GW; Felberg R; Herrmann H; Kar S; Landzberg M; Raizner A; Wechsler L;
    N Engl J Med; 2012 Mar; 366(11):991-9. PubMed ID: 22417252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of Persistent Right-to-Left Shunt After Patent Foramen Ovale Closure in Cryptogenic Stroke Patients.
    He L; Cheng G; Du Y; Zhang Y
    Tex Heart Inst J; 2020 Aug; 47(4):244-249. PubMed ID: 33472221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
    Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Asmarats L; Côté M; Rodés-Cabau J
    J Am Coll Cardiol; 2019 Jan; 73(3):278-287. PubMed ID: 30678757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Sagris D; Makaritsis K; Vemmos K; Steiner T; Michel P
    Stroke; 2018 Feb; 49(2):412-418. PubMed ID: 29335335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale.
    Furlan AJ; Reisman M; Massaro J; Mauri L; Adams H; Albers GW; Felberg R; Herrmann H; Kar S; Landzberg M; Raizner A; Wechsler L;
    Stroke; 2010 Dec; 41(12):2872-83. PubMed ID: 21051670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
    Meier B; Kalesan B; Mattle HP; Khattab AA; Hildick-Smith D; Dudek D; Andersen G; Ibrahim R; Schuler G; Walton AS; Wahl A; Windecker S; Jüni P;
    N Engl J Med; 2013 Mar; 368(12):1083-91. PubMed ID: 23514285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
    Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
    Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.
    Pickett CA; Villines TC; Ferguson MA; Hulten EA
    Tex Heart Inst J; 2014 Aug; 41(4):357-67. PubMed ID: 25120387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of device closure of patent foramen ovale in patients with cryptogenic stroke.
    Fukutomi M; Wilkins B; Søndergaard L
    J Intern Med; 2020 Oct; 288(4):400-409. PubMed ID: 32812297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis.
    Sagris D; Georgiopoulos G; Perlepe K; Pateras K; Korompoki E; Makaritsis K; Vemmos K; Milionis H; Ntaios G
    Stroke; 2019 Nov; 50(11):3135-3140. PubMed ID: 31547797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodality imaging approach of patent foramen ovale: Practical considerations for transient ischemic attack/stroke.
    Floria M; Năfureanu ED; Iov DE; Dranga M; Popa RF; Baroi LG; Sascău RA; Stătescu C; Tănase DM
    J Clin Ultrasound; 2022 Oct; 50(8):1166-1176. PubMed ID: 36218207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism.
    Agarwal S; Bajaj NS; Kumbhani DJ; Tuzcu EM; Kapadia SR
    JACC Cardiovasc Interv; 2012 Jul; 5(7):777-89. PubMed ID: 22814784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent foramen ovale and cryptogenic stroke: the hole story.
    Furlan AJ; Jauss M
    Stroke; 2013 Sep; 44(9):2676-8. PubMed ID: 23908069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
    Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Outcomes after Device Closure and Medication Alone in Patients with Patent Foramen Ovale and Cryptogenic Stroke in Korean Population.
    Moon J; Kang WC; Kim S; Oh PC; Park YM; Chung WJ; Choi DY; Lee JY; Lee YB; Hwang HY; Ahn T
    Yonsei Med J; 2016 May; 57(3):621-5. PubMed ID: 26996560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years of experience with closure of persistent foramen ovale: patient characteristics and outcomes.
    Lehmann R; Fichtlscherer S; Baldauf H; Schächinger V; Auch-Schwelck W; Zeiher AM; Teupe C
    J Cardiol; 2014 Aug; 64(2):113-6. PubMed ID: 24480741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.